Nicolas Bigot

@nicolab.bsky.social

Studying #DNA3R and teaching in #Paris

The Thermo Fisher situation keeps getting worse. We've now collected 450+ problematic images presented as verification data in TF's antibody catalog. This includes: 🖌️ Dozens more images with duplications or painting 🖨️ Hundreds of blots that all share the same background (behold slideshow below)

Another great opportunity for genome integrity / replication stress aficionados to attend two excellent seminars with a simple click. Join us in a few days (Tue April 7th)! 👇

Bild

And in yesterday's journal club, we discussed this nice paper on transforming antibodies into intrabodies from @tim-stasevich.bsky.social et al. The authors put together a pipeline comprising ProteinMPNN to design a stabler protein sequence for the scaffold while keeping the antigen-binding loops.

AI-assisted protein design to rapidly convert antibody sequences to intrabodies targeting diverse peptides and histone modifications

AI-powered pipeline converts antibodies into functional intrabodies, enabling live-cell imaging of peptides and histone marks.

science.org

In this study, we reveal that OGG1’s association with DNA during lesion searching involves local DNA distortion, promoting base unstacking. This process is tightly regulated by conserved amino acids encircling the double helix, ensuring stable binding without compromising rapid scanning.

Exciting new study from new-PI Mohinder Pal on the role of CCDC103 and it's links to PCD as the most recent dynein assembly factor (DNAAF19). Congratulations to the entire team. @Mohinder Pal (currently not on Bluesky) @mike-wieczorek.bsky.social @laurencepearl.bsky.social

UK Cilia and Centrosome Network@ukcilianetwork.bsky.social · 11mo ago

New pre-print on the role of CCDC103/DNAAF19 in dynein assembly highlighting it's link to PCD. www.biorxiv.org/content/10.1...

Academic research generates almost all intellecutal innovation in the life sciences. With big pharma refusing to contribute, maybe it's time to stop giving them our research outputs cheaply, and instead having globally nationalised means of translating innovation? www.theguardian.com/business/202...

US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs

New blow to UK’s key life science sector as industry body says country is losing ground on investment and research

theguardian.com